Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | ACP1 | P24666 | 3/20 | 0.36 |
| ▸ | CDC25B | P30305 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28718996 | 0.79 | CYP1A2 (0.42) | CYP1A2PRKCA | |
| SCHEMBL11865670 | 0.75 | — | — | |
| SCHEMBL9508162 | 0.72 | TDP1 (0.35) | ALDH1A1CYP1A2 | |
| SCHEMBL28108927 | 0.68 | CYP1A2 (0.43) | ALDH1A1CYP1A2PRKCACYP2C19 | |
| SCHEMBL11087724 | 0.66 | CYP1A2 (0.37) | ALDH1A1CYP1A2PTPN1ACP1CDC25B | |
| SCHEMBL10073523 | 0.65 | CYP1A2 (0.39) | CYP1A2PTPN1ACP1CDC25BPOLB | |
| SCHEMBL713890 | 0.65 | CYP1A2 (0.39) | CYP1A2PTPN1ACP1CDC25BPOLB | |
| SCHEMBL1772842 | 0.65 | SIRT2 (0.34) | ALDH1A1CYP1A2PRKCAL3MBTL1 | |
| SCHEMBL13177714 | 0.64 | ALDH1A1 (0.47) | ALDH1A1CYP1A2PRKCA | |
| SCHEMBL8045560 | 0.64 | ALDH1A1 (0.47) | ALDH1A1CYP1A2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186604-B2 | Non-caloric sweeteners and methods for synthesizing | CONAGEN INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200339621-A1 | NON-CALORIC SWEETENERS AND METHODS FOR SYNTHESIZING | CONAGEN INC. (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186604-B2 | Non-caloric sweeteners and methods for synthesizing | GCKR, ME3, SUCLG2 | ALDH1A1 2766/4885CYP1A2 2819/4885PTPN1 2855/4885 |
| US-20200339621-A1 | NON-CALORIC SWEETENERS AND METHODS FOR SYNTHESIZING | GCKR, ME3, SUCLG2 | ALDH1A1 2766/4885CYP1A2 2819/4885PTPN1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.